Checkpoint Therapeutics, Inc. Contracts & Agreements

Form of Securities Purchase Agreement, dated as of July 2, 2024, by and between Checkpoint Therapeutics, Inc. and the Purchaser (Filed With SEC on July 3, 2024)

Form of Placement Agent Warrant (Filed With SEC on July 3, 2024)

Form of Common Stock Purchase Warrant (Filed With SEC on July 3, 2024)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on July 3, 2024)

Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (Filed With SEC on May 14, 2024)

Amended and Restarted Non-Employee Directors Compensation Plan (Filed With SEC on May 10, 2024)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 22, 2024)

Mutual Termination Agreement (Sublicense) by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated September 30, 2023 (Filed With SEC on March 22, 2024)

Mutual Termination Agreement (Collaboration) by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated September 30, 2023 (Filed With SEC on March 22, 2024)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on January 30, 2024)

Form of Common Stock Purchase Warrant (Filed With SEC on January 30, 2024)

Form of Placement Agent Warrant (Filed With SEC on January 30, 2024)

Form of Securities Purchase Agreement, dated as of January 27, 2024, by and between Checkpoint Therapeutics, Inc. and the Purchaser (Filed With SEC on January 30, 2024)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on October 3, 2023)

Form of Placement Agent Warrant (Filed With SEC on October 3, 2023)

Form of Inducement Letter Agreement, dated as of October 2, 2023, by and between Checkpoint Therapeutics, Inc. and the Holder (Filed With SEC on October 3, 2023)

Amended and Restated Non-Employee Directors Compensation Plan (Filed With SEC on August 14, 2023)

Form of Securities Purchase Agreement, dated as of July 28, 2023, by and between Checkpoint Therapeutics, Inc. and the Purchasers (Filed With SEC on July 31, 2023)

Form of Placement Agent Warrant (Filed With SEC on July 31, 2023)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on July 31, 2023)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on July 31, 2023)

Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (Filed With SEC on June 13, 2023)

Form of Securities Purchase Agreement, dated as of May 23, 2023, by and between Checkpoint Therapeutics, Inc. and the Purchaser (Filed With SEC on May 24, 2023)

Form of Placement Agent Warrant (Filed With SEC on May 24, 2023)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on May 24, 2023)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on May 24, 2023)

Securities Purchase Agreement, dated as of March 30, 2023, by and between Checkpoint Therapeutics, Inc. and the Purchasers (Filed With SEC on April 4, 2023)

Form of Placement Agent Warrant (Filed With SEC on April 4, 2023)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on April 4, 2023)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 31, 2023)

Form of Placement Agent Warrant (Filed With SEC on February 22, 2023)

Securities Purchase Agreement, dated as of February 20, 2023, by and between Checkpoint Therapeutics, Inc. and the Purchaser (Filed With SEC on February 22, 2023)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on February 22, 2023)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on February 22, 2023)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on December 16, 2022)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on December 16, 2022)

Form of Placement Agent Warrant (Filed With SEC on December 16, 2022)

Securities Purchase Agreement, dated as of December 14, 2022, by and between Checkpoint Therapeutics, Inc. and the Purchaser (Filed With SEC on December 16, 2022)

Amendment to Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (Filed With SEC on December 5, 2022)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 28, 2022)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 12, 2021)

Master Services Agreement between Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc., effective November 8, 2017 (Filed With SEC on November 6, 2020)

Amendment No. 5, dated September 24, 2020, to the Executive Employment Agreement dated October 13, 2015, by and between Checkpoint Therapeutics, Inc. and James F. Oliviero III (Filed With SEC on November 6, 2020)

Underwriting Agreement, entered into by and between Checkpoint Therapeutics, Inc. and H.C. Wainwright & Co., LLC, on September 17, 2020 (Filed With SEC on September 21, 2020)

Amendment to Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (Filed With SEC on June 4, 2020)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 11, 2020)

Underwriting Agreement, entered into by Checkpoint Therapeutics, Inc. on November 20, 2019, with National Securities Corporation (Filed With SEC on November 20, 2019)

Amendment No. 4, dated October 7, 2019, to the Executive Employment Agreement dated October 13, 2015, by and between Checkpoint Therapeutics, Inc. and James F. Oliviero III (Filed With SEC on November 12, 2019)

Amended and Restated Collaboration Agreement by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated June 19, 2019 (Filed With SEC on August 8, 2019)

Collaboration Agreement by and between Adimab, LLC and Checkpoint Therapeutics, Inc., dated January 22, 2019 (Filed With SEC on March 18, 2019)

Certificate of Amendment of Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., dated June 14, 2018 (Filed With SEC on August 7, 2018)

Amendment No. 3, dated January 30, 2018, to the Executive Employment Agreement dated October 13, 2015, by and between Checkpoint Therapeutics, Inc. and James F. Oliviero III (Filed With SEC on March 16, 2018)

Extension dated December 29, 2017, to Option Agreement by and between Fortress Biotech, Inc. and TG Therapeutics, Inc., dated March 17, 2015 (assigned to Checkpoint Therapeutics,... (Filed With SEC on March 16, 2018)

Underwriting Agreement, entered into by Checkpoint Therapeutics, Inc. on March 8, 2018, with National Securities Corporation (Filed With SEC on March 8, 2018)

First Amendment to Amended and Restated Founders Agreement (Filed With SEC on November 3, 2017)

CHECKPOINTTHERAPEUTICS, INC. AMENDEDAND RESTATED 2015 INCENTIVEPLAN ARTICLE1 PURPOSE (Filed With SEC on August 9, 2017)

AMENDED& RESTATED CHECKPOINT THERAPEUTICS, INC. NON-EMPLOYEEDIRECTORS COMPENSATION PLAN (Filed With SEC on August 9, 2017)

SECOND AMENDMENT TO SUBLICENSE AGREEMENT (Filed With SEC on May 10, 2017)

SECOND AMENDMENT TO LICENSE AGREEMENT(Amendment # 2) (Filed With SEC on May 10, 2017)

FIRST AMENDMENT TO SUBLICENSE AGREEMENT (Filed With SEC on March 17, 2017)

FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on March 17, 2017)

EXTENSION OF OPTION AGREEMENT (Filed With SEC on March 17, 2017)

BOARD ADVISORY SERVICES AGREEMENT (Filed With SEC on March 17, 2017)

SECOND AMENDMENT TO EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on March 17, 2017)

FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on March 17, 2017)

Amendment 3 to Exclusive License Agreementbetween Checkpoint Therapeutics, Inc. and Dana-FarberCancer Institute, Inc. (Filed With SEC on March 17, 2017)

Amendment 2 to Exclusive License Agreementbetween Checkpoint Therapeutics, Inc. and Dana-FarberCancer Institute, Inc. (Filed With SEC on March 17, 2017)

AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on October 3, 2016)

Category

Industry

Companies

Contracts

Checkpoint Therapeutics, Inc. Contracts & Agreements